Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis

PHASE2CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

February 6, 2018

Primary Completion Date

December 21, 2020

Study Completion Date

December 21, 2020

Conditions
Active Ulcerative Colitis
Interventions
DRUG

TJ301 300mg

TJ301 300mg IV infusion

DRUG

TJ301 600mg

TJ301 600mg IV infusion

DRUG

Placebo

Placebo IV infusion

Trial Locations (27)

100034

Peking University First Hospital, Beijing

510080

The First Affiliated Hospital, Sun Yat-sen University, Guanzhou

510655

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou

610000

West China Hospital of Sichuan University, Sichuan

Unknown

Beijing Friendship Hospital Affiliated to the Capital University of Medical Sciences, Beijing

The Seventh Medical Center of PLA Army General Hospital, Beijing

Guangdong Provincial People's Hospital, Guangzhou

Nanfang Hospital of SMU, Guangzhou

Hainan General Hospital, Hainan

Sir Run Run Shaw Hospital Zhejiang University, School of Medicine, Zhejiang

The First Affiliated Hospital of Harbin Medical University, Harbin

The first Bethune hospital of Jilin university, Jilin

The first affiliated hospital of Nanchang Univesity, Nanchang

Jiangsu Province Hospital, Nanjing

The Affiliated Hospital of Nanjing University Medical School, Nanjing

Zhongda Hospital Southeast University, Nanjing

Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

Xin Hua Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai

Shengjing hospital of China medical university, Shenyang

Second Hospital of Shanxi Medical University, Shanxi

Tianjin Medical University General Hospital, Tianjin

Yeungnam University Medical Center, Daegu

CHA Bundang Medical Center, CHA University, Seoul

National Taiwan University Hospital, Kaohsiung City

Chang Gung Memorial Hospital, Taipei

Chang Gung Memorial Hospital, Taoyuan District

All Listed Sponsors
lead

I-Mab Biopharma HongKong Limited

INDUSTRY

NCT03235752 - Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis | Biotech Hunter | Biotech Hunter